← Back to search
INTRAVACC B.V.
BILTHOVEN, 3721M
Unclaimed
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM. | — | $9,042,149 | Aug 20, 2026 | Sep 1, 2020 – May 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA BASED ON OUTER MEMBRANE VESICLES COMBINED WITH SUSTAINED-RELEASE MICROSPHERES CONTAINING RECOMBINANT HUMAN INTERLEUKIN-12. | — | $6,612,767 | Jan 14, 2026 | Sep 21, 2022 – Dec 30, 2026 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | ONORRHEA IS A SEXUALLY TRANSMITTABLE DISEASE THAT IS CAUSED BY INFECTION WITH NEISSERIA GONORRHOEAE BACTERIA (ALSO KNOWN AS GONOCOCCI). IT AFFECTS CLOSE TO 100 MILLION PEOPLE WORLDWIDE ON A YEARLY BASIS AND ALTHOUGH MORTALITY IS LOW, THE DISEASE CAN HAVE SEVERE HEALTH CONSEQUENCES LIKE INFERTILITY, NEONATAL BLINDNESS, AND INCREASED RISK OF HIV INFECTION. ANTIBIOTIC-BASED TREATMENT IS UNDER INCREASED PRESSURE BECAUSE OF THE RISE OF MULTI DRUG RESISTANCE STRAINS AND IN SOME CASES, CLINICIANS HAVE TO RESORT TO SO-CALLED €ˌLAST LINE€„¢ ANTIBIOTICS. VACCINE DEVELOPMENT AGAINST GONOCOCCI HAS FOR DECADES BEEN HAMPERED BY THE MULTITUDE OF WAYS THAT THESE BACTERIA USE TO EVADE THE HUMAN IMMUNE SYSTEM AS WELL AS THEIR STRONG GENETIC VARIATION. CURRENTLY NO VACCINE AGAINST GONORRHEA IS AVAILABLE. IT HAS RECENTLY BEEN FOUND THAT PEOPLE THAT HAVE PREVIOUSLY BEEN VACCINATED AGAINST MENINGITIS USING OUTER MEMBRANE VESICLES (OMVS) HARVESTED FROM NEISSERIA MENINGITIDIS, A CLOSE RELATIVE OF THE GONOCOCCUS, HAVE A REDUCED RISK OF CONTRACTING GONORRHEA. INTRAVACC IS DEVELOPING A VACCINE FOR GONORRHEA BASED ON ITS NEISSERIA MENINGITIDIS OMV PLATFORM TECHNOLOGY. THE NEISSERIA MENINGITIDIS BACTERIA ARE DESIGNED TO EXPRESS NEISSERIA GONORRHOEAE ANTIGENS ON THEIR SURFACE THAT ARE CONSERVED AMONG STRAINS AND/OR IMPORTANT FOR GROWTH, AND CAPABLE OF INDUCING BACTERICIDAL ANTIBODIES, THEREBY ENSURING BROAD PROTECTION AND STRAIN COVERAGE. IN ADDITION, THE IMMUNOGENICITY OF THE NEISSERIA GONORRHOEAE PROTEINS IS OPTIMIZED BY THE HETEROLOGOUS EXPRESSION OF THESE ANTIGENS IN NEISSERIA MENINGITIDIS. THIS ENSURES BETTER NATURAL FOLDING OF THE PROTEINS AS COMPARED TO RECOMBINANT PROTEINS. THIS HETEROLOGOUS MENINGOCOCCAL OMV VACCINE FOR PREVENTION OF NEISSERIA GONORRHOEAE IS EXPECTED TO HAVE A CONSIDERABLY INCREASED EFFECTIVENESS AGAINST GONORRHEA. IN THIS CARB-X FUNDED PROJECT INTRAVACC AIMS TO DEVELOP THIS NOVEL VACCINE CONCEPT NAMED AVACC 12 UP TO A FIRST IN HUMAN STUDY. 4500004853 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $31,656 | Dec 7, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced